close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

8.26 -2.02

Strong Buy

Prijsupdate 30 apr 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.13

Max

8.64

Belangrijke statistieken

By Trading Economics

Inkomsten

-69M

-102M

Verkoop

-10M

34M

EPS

-5.69

Winstmarge

-299.886

Werknemers

228

EBITDA

4.7M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+97.62% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

38M

195M

Vorige openingsprijs

10.28

Vorige sluitingsprijs

8.26

Nieuwssentiment

By Acuity

50%

50%

186 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 apr 2026, 23:08 UTC

Winsten

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

DJ

Lezen

30 apr 2026, 23:07 UTC

Winsten

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

DJ

Lezen

30 apr 2026, 22:20 UTC

Winsten

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

DJ

Lezen

30 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

DJ

Lezen

30 apr 2026, 23:47 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

30 apr 2026, 23:47 UTC

Marktinformatie

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

DJ

Lezen

30 apr 2026, 23:27 UTC

Marktinformatie

Liontown Lithium Recovery Expected to Improve -- Market Talk

DJ

Lezen

30 apr 2026, 23:22 UTC

Winsten

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

DJ

Lezen

30 apr 2026, 23:20 UTC

Marktinformatie

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

DJ

Lezen

30 apr 2026, 22:52 UTC

Winsten

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

DJ

Lezen

30 apr 2026, 22:33 UTC

Winsten

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

DJ

Lezen

30 apr 2026, 22:32 UTC

Winsten

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

DJ

Lezen

30 apr 2026, 22:32 UTC

Winsten

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

DJ

Lezen

30 apr 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

DJ

Lezen

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

DJ

Lezen

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

DJ

Lezen

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

DJ

Lezen

30 apr 2026, 22:11 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

30 apr 2026, 22:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

30 apr 2026, 22:11 UTC

Marktinformatie

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

DJ

Lezen

30 apr 2026, 22:05 UTC

Winsten

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

DJ

Lezen

30 apr 2026, 21:57 UTC

Winsten

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

DJ

Lezen

30 apr 2026, 21:56 UTC

Winsten

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

DJ

Lezen

30 apr 2026, 21:56 UTC

Winsten

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

DJ

Lezen

30 apr 2026, 21:55 UTC

Winsten

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

DJ

Lezen

30 apr 2026, 21:54 UTC

Winsten

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

DJ

Lezen

30 apr 2026, 21:54 UTC

Winsten

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

DJ

Lezen

30 apr 2026, 21:53 UTC

Winsten

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

DJ

Lezen

30 apr 2026, 21:49 UTC

Winsten

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

DJ

Lezen

30 apr 2026, 21:49 UTC

Winsten

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

97.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.6 USD  97.62%

Hoogste 28 USD

Laagste 8 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

186 / 347 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

JNJ

Johnson and Johnson

229.87

↑ +1.14%

UNH

UnitedHealth Group Inc

370.84

↑ +0.14%

TMO

Thermo Fisher Scientific Inc

478.44

↑ +2.91%

ISRG

Intuitive Surgical Inc

457.44

↑ +1.12%

ABT

Abbott Laboratories

90.76

↓-0.82%
help-icon Live chat